Comparison of time to failure of pembrolizumab plus chemotherapy versus pembrolizumab monotherapy: a consecutive analysis of patients having NSCLC with high PD-L1 expression.
Hiroshi TakumidaHidehito HorinouchiKen MasudaYuki ShinnoYusuke OkumaTatsuya YoshidaYasushi GotoNoboru YamamotoYuichiro OhePublished in: Cancer immunology, immunotherapy : CII (2021)
Due to similar efficacy in TFS, both pembrolizumab plus chemotherapy and monotherapy are valid options for NSCLC.